Two Sigma Investments LP purchased a new stake in shares of aTyr Pharma Inc (NASDAQ:LIFE) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 64,269 shares of the biotechnology company’s stock, valued at approximately $180,000. Two Sigma Investments LP owned about 0.69% of aTyr Pharma at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Federated Hermes Inc. grew its position in shares of aTyr Pharma by 171.4% in the 1st quarter. Federated Hermes Inc. now owns 1,615,000 shares of the biotechnology company’s stock worth $4,522,000 after buying an additional 1,019,928 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in aTyr Pharma in the first quarter worth $2,067,000. Viking Global Investors LP lifted its stake in aTyr Pharma by 156.2% in the first quarter. Viking Global Investors LP now owns 587,444 shares of the biotechnology company’s stock worth $1,645,000 after acquiring an additional 358,161 shares during the period. Renaissance Technologies LLC boosted its holdings in aTyr Pharma by 3.3% in the fourth quarter. Renaissance Technologies LLC now owns 199,920 shares of the biotechnology company’s stock valued at $834,000 after acquiring an additional 6,300 shares in the last quarter. Finally, UBS Group AG increased its position in aTyr Pharma by 1,002.1% during the 1st quarter. UBS Group AG now owns 37,999 shares of the biotechnology company’s stock valued at $106,000 after purchasing an additional 34,551 shares during the period. Institutional investors and hedge funds own 56.22% of the company’s stock.
A number of equities research analysts have recently weighed in on the stock. Roth Capital began coverage on shares of aTyr Pharma in a research note on Wednesday, March 4th. They set a “buy” rating and a $15.00 target price on the stock. Zacks Investment Research cut aTyr Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, June 24th. HC Wainwright reiterated a “hold” rating on shares of aTyr Pharma in a report on Tuesday, April 21st. Finally, Oppenheimer restated a “buy” rating and issued a $8.00 target price on shares of aTyr Pharma in a research note on Tuesday, June 16th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $7.95.
aTyr Pharma (NASDAQ:LIFE) last released its earnings results on Tuesday, May 12th. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.43. aTyr Pharma had a negative net margin of 185.14% and a negative return on equity of 52.40%. The firm had revenue of $8.07 million during the quarter, compared to analyst estimates of $4.40 million. On average, equities research analysts expect that aTyr Pharma Inc will post -2.33 earnings per share for the current fiscal year.
In related news, CEO Sanjay Shukla acquired 6,000 shares of the stock in a transaction on Friday, June 19th. The stock was acquired at an average price of $4.27 per share, for a total transaction of $25,620.00. Following the completion of the purchase, the chief executive officer now owns 7,291 shares of the company’s stock, valued at $31,132.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 9.44% of the stock is owned by company insiders.
aTyr Pharma Profile
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD.
Recommended Story: Monthly Dividend Stocks Can Provide Solid Income
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.